Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype

Experimental Oncology

Volumn 35, Issue 3, 2013, Pages 174-179

  Chekhun, S ^a   Bezdenezhnykh, N ^a   Shvets, J ^a   Lukianova, N ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Adhesion molecules; Basal subtype; Breast cancer; Cancer stem cells; CD24; CD44; Cell lines; E cadherin; Luminal subtype

Indexed keywords

BIOLOGICAL MARKER; CD24 ANTIGEN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CELL ADHESION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; PROTEIN EXPRESSION; TUMOR INVASION;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892157410     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Andreopoulou E, Gortobagyi G. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2013; 1: 3660-3662
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62: 10-29
3. Cianfrocca M, Goldstein L. Prognostic and Predictive Factors in Early-Stage Breast Cancer. The Oncologist 2004; 9: 606-616
4. Viale G. The current state of breast cancer classification. Ann Oncol 2012; 23 (suppl 10): 207-210
5. Khokher S, Qureshi MU, Mahmood S, Nagi AH. Association of Immunohistochemically Defined Molecular Subtypes with Clinical Response to Presurgical Chemotherapy in Patients with Advanced Breast Cancer. Asian Pacific J Cancer Prev 2013; 14: 3223-3228
6. Zelnak AB, O'Regan RM. Genomic subtypes in choosing adjuvant therapy for breast cancer. Oncology (Williston Park) 2013; 27: 204-210
7. Masuda S. Genomic diagnosis in breast cancer practice. Rinsho Byori 2012; 60: 969-74
8. Langlands FE, Horgan K, Dodwell DD, Smith L. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol 2013; 86: 20120601. doi: 10.1259/bjr.20120601
9. Guiu S, Michiels S, André F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012; 23: 2997-3006
10. Lips EH, Mulder L, de Ronde JJ, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 2013; 140: 63-71
11. Boyle DP, McCourt CM, Matchett KB, et al. Molecular and clinicopathological markers of prognosis in breast cancer. Expert Review of Molecular Diagnostics 2013; 13: 481-498
12. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12: 621-628
13. Polishchuk LZ, Ryabtseva OD, Lukianova NYu, et al. Adhesion molecules and their role in development of malignant neoplasms. Oncologiya 2011, 13: 4-11
14. Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. British Journal of Cancer 2013; 108: 755-761
15. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751
16. Simon M, Stefan N, Plückthun A, et al. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv 2013; 10: 451-68
17. Williams K, Motiani K, Giridhar PV, et al. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre) metastatic niches. Exp Biol Med (Maywood) 2013; 238: 324-38
18. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 2011; 128: 7-21
19. Gangopadhyay S, Nandy A, Hor P, et al. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2012, 13: 7-15
20. Gritsenko PG, Ilina O, Friedl P. Interstitial guidance of cancer invasion. J Pathol 2012; 226: 185-99
21. Shevde LA, Das S, Clark DW, et al. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010; 10: 71-81
22. Radisky ES, Radisky DC. Matrix Metalloproteinase- Induced Epithelial-Mesenchymal Transition in Breast Cancer. J Mammary Gland Biol Neoplasia 2010; 15, 201-212
23. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008; 65: 3756-3788
24. Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis. Acta histochemica 2010; 1: 3-25
25. Voutilainen KA, Anttila MA, Sillan SM, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 2006; 59: 460-467
26. Bánkfalvi A, Krassort M, Buchwalow I, et al. Gains and losses of adhesion molecules (CD44, E-cadherin, and betacatenin) during oral carcinogenesis and tumour progression. J Pathol 2002; 198: 343-351
27. Nieman MT, Prudoff RS, Johnson KR, et al. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999; 147: 631-44
28. Nagi C, Guttman M, Jaffer S, et al. N-cadherin expression in breast cancer: correlation with an aggressive histologic variant - invasive micropapillary carcinoma. Breast Cancer Res Treat 2005; 94: 225-35
29. Buda A, Pignatelli M. E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. Cell Commun Adh 2011; 18: 133-143
30. Hazan RB, Kang L, Whooley BP, et al. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 1997; 4: 399-411
31. Marhaba R, Klingbeil P, Nuebel T, et al. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 2008; 8: 784-804
32. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine 2013; 8: 899-908
33. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/ CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2011; 43: 364-373
34. McCelland RA, Wilson D, Leake R. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991; 27: 711-715
35. Li L, Mu K, Zhou G, et al. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. BJC 2008; 99: 513-519
36. Bonetti A, Zaninelli M, Rodella S, et al. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat 1996; 38: 289-97
37. Ohashi K, Nemoto T, Eishi Y, et al. Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in oesophageal squamous cell carcinomas. Virchows Arch 1997; 420: 107-115
38. Wang LH, Liu DY, Chen YJ, et al. Relationship between lymph node metastasis and the expressions of E-cadherin, N-cadherin, and matrix metalloproteinase in breast carcinoma. Ai Zheng 2002; 21: 965-969
39. Lesley J, Hyman R, English N, et al. CD44 in inflammation and metastasis. Glycoconj J 1997; 14: 611-22